

Table of Contents

<i>Certificates</i>	<i>ii</i>
<i>Acknowledgement</i>	<i>v</i>
<i>List of abbreviations</i>	<i>vii</i>
<i>List of tables</i>	<i>x</i>
<i>List of figures</i>	<i>xi</i>
<i>Preface</i>	<i>xiv</i>

Chapter 1

1.Introduction and literature review	1
1.1 Introduction	1
1.1.1 <i>The Amorphous state and its stability</i>	4
1.2 Factors affecting physical stability of ASD	5
1.2.1 <i>Glass forming ability and glass stability</i>	6
1.2.2 <i>Glass transition temperature of drug</i>	8
1.2.3 <i>Glass transition temperature of polymer</i>	9
1.2.4 <i>Interactions within ASDs</i>	11
1.2.3.1 <i>Hydrogen Bonding</i>	13
1.2.3.2 <i>Ionic interaction</i>	13
1.2.3.3 <i>Dipole dipole interaction</i>	13
1.2.3.4 <i>Hydrophobic interaction</i>	14
1.2.3.5 <i>Ion dipole interaction</i>	14
1.2.3.6 <i>Halogen bonding</i>	15
1.2.5 <i>Miscibility of drug and polymer</i>	15
1.2.6 <i>Hygroscopicity</i>	16
1.2.7 <i>Drug loading</i>	16
1.2.8 <i>Ternary excipients</i>	18
1.2.9 <i>Manufacturing factors</i>	18
1.2.9.1 <i>Particle size/porosity</i>	18
1.2.9.2 <i>Drug-polymer mixing</i>	18
1.2.9.3 <i>Compression</i>	19
1.2.9.4 <i>Residual solvent</i>	19
1.2.10 <i>Environmental factors</i>	19
1.3 Method of Preparation of ASDs	20
1.3.1 <i>Hot Melt Extrusion</i>	20
1.3.2 <i>Solvent evaporation</i>	21
1.3.2.1 <i>Solvent casting</i>	21
1.3.2.1 <i>Spray Drying Technique</i>	22
1.3.3 <i>Solvent evaporation at reduced pressure</i>	23
1.3.4 <i>Freeze Drying</i>	23

1.3.5	<i>Supercritical Fluids</i>	24
1.4	Applications of Analytical Techniques for the Characterization of ASD	25
1.4.1	<i>Thermal techniques of analysis</i>	25
1.4.1.1	<i>Thermogravimetric Analysis</i>	25
1.4.1.2	<i>Calorimetric techniques</i>	25
1.4.2	<i>Morphological and Microscopic Techniques</i>	28
1.4.2.1	<i>Polarized light microscopy and hot-stage polarized light microscopy</i>	29
1.4.2.2	<i>Scanning electron microscopy</i>	30
1.4.2.3	<i>Transmission electron microscopy</i>	30
1.4.2.4	<i>Atomic force microscopy</i>	30
1.4.2.5	<i>Powder X-ray Diffraction</i>	31
1.4.3	<i>Spectroscopic Techniques</i>	31
1.4.3.1	<i>Infrared spectroscopy and Raman spectroscopy</i>	31
1.4.3.2	<i>Solid-state NMR</i>	32
1.5	Polymer matrices for ASD preparation	34
1.5.1	<i>Physicochemical properties of polymers used in ASD</i>	35
1.5.2	<i>Polyvinyl lactam polymers</i>	36
1.5.2.1	<i>Copovidone (PVP VA)</i>	36
1.5.3	<i>Cellulosic polymers</i>	37
1.5.3.1	<i>Hypromellose acetate succinate</i>	38
1.5.4	<i>Acrylate and methacrylate (co-) polymers</i>	39
1.5.5	<i>Other Polymers</i>	39
1.5.5.1	<i>Polyacrylic Acid</i>	39
1.6	Riluzole	44
1.6.1	<i>Mechanism of Action of Riluzole</i>	44
1.6.2	<i>Physicochemical Properties of RLZ</i>	44
1.6.3	<i>Associated Toxicity with RLZ</i>	45
1.6.4	<i>Pharmacokinetics of RLZ</i>	45
1.6.5	<i>Marketed formulations of RLZ</i>	46
1.7	Physiological Based Pharmacokinetic Modelling	46

Chapter 2

2 Materials

2.1	Materials	49
2.2	Equipment	50
2.3	Software	51

Chapter 3

3 Molecular Interactions-Assisted Grading of Polymers for the Development of Stable Amorphous Solid Dispersion of Riluzole

3.1	Background of the study	53
3.1.1	<i>Plan of work</i>	53
3.2	Experimental section	54
3.2.1	<i>Methodology for in silico studies</i>	54
3.2.1.1	<i>Preparation of 3D Structures of Polymers</i>	54
3.2.1.2	<i>Molecular docking</i>	55
3.2.1.3	<i>Molecular dynamics simulations (MDS)</i>	56
3.2.1.4	<i>Density functional theory (DFT) calculations</i>	56
3.2.2	<i>Development of amorphous solid dispersion of RLZ and physical mixtures of RLZ with polymers</i>	57
3.2.3	<i>Powder X-ray diffraction study</i>	58
3.2.4	<i>Determination of melting point and glass transition temperature</i>	58
3.2.5	<i>FT-IR characterization</i>	59
3.2.6	<i>Solid-state NMR</i>	59
3.2.7	<i>Crystallization tendency of amorphous solid dispersion</i>	59
3.2.8	<i>Microscopic analysis</i>	60
3.2.9	<i>Drug polymer miscibility study and phase diagram</i>	60
3.2.9.1	<i>Melting Point Depression Study</i>	60
3.2.9.2	<i>True density</i>	61
3.2.10	<i>Long term stability study</i>	61
3.3	Results and Discussion	61
3.3.1	<i>In silico studies</i>	61
3.3.1.1	<i>Preparation of 3D structures of polymers</i>	61
3.3.1.2	<i>Drug-polymer interaction</i>	63
3.3.2	<i>Powder X-ray diffraction study</i>	68
3.3.3	<i>Determination of melting point and glass transition temperature</i>	70
3.3.4	<i>FT-IR characterization</i>	72
3.3.5	<i>Solid-state NMR</i>	73
3.3.6	<i>Crystallization tendency of amorphous solid dispersion</i>	77
3.3.7	<i>Microscopic analysis</i>	79
3.3.8	<i>Drug polymer miscibility and phase diagram</i>	81
3.3.9	<i>Long term stability studies</i>	90
3.4	Conclusions	91

Chapter 4

4 Impact of surface properties on drug dissolution in amorphous solid dispersion of Riluzole prepared with different polymers

4.1	Background of the study	93
4.1.1	<i>Plan of work</i>	94
4.2	Experimental section	95
4.2.1	<i>Nuclear Magnetic Resonance</i>	95

4.2.2	<i>Preparation of amorphous solid dispersion of RLZ</i>	95
4.2.3	<i>Saturation solubility in presence of polymer</i>	95
4.2.4	<i>In vitro dissolution study</i>	96
4.2.5	<i>Wetting property and surface free energy</i>	96
4.2.6	<i>X-ray Photoelectron Spectroscopy</i>	97
4.3	Results and Discussion	98
4.3.1	<i>Nuclear Magnetic Resonance</i>	98
4.3.2	<i>Saturation solubility in presence of polymer</i>	99
4.3.3	<i>In vitro Dissolution Study</i>	100
4.3.4	<i>Wetting property and surface free energy</i>	102
4.3.5	<i>X-Ray Photoelectron Spectroscopy</i>	105
4.4	Conclusions	109

Chapter 5

5 PBPK modelling for pharmacokinetic simulation and pharmacodynamic evaluation of the RLZ ASD

5.1	Background of the study	111
5.1.1	<i>Plan of work</i>	111
5.2	Experimental section	112
5.2.1	<i>Preparation of amorphous solid dispersion of RLZ</i>	112
5.2.2	<i>Solid-state Characterization</i>	112
5.2.2.1	<i>Powder X-Ray Diffraction Study</i>	112
5.2.2.2	<i>Differential Scanning Calorimetry Study</i>	113
5.2.2.3	<i>Transmission Electron Microscopy</i>	113
5.2.3	<i>High Performance Liquid Chromatography Method Development and Validation</i>	113
5.2.4	<i>Biopharmaceutical Performance Evaluation</i>	114
5.2.4.1	<i>Saturation solubility study</i>	114
5.2.4.2	<i>In vitro dissolution testing</i>	114
5.2.4.3	<i>Plasma and brain pharmacokinetics in male rats</i>	114
5.2.5	<i>Literature Data Extraction for PBPK modeling</i>	116
5.2.5.1	<i>Rat Literature Experimental Data</i>	116
5.2.5.2	<i>Human Literature Experimental Data</i>	116
5.2.5.3	<i>Development and optimization of the PBPK model</i>	116
5.2.5.4	<i>Model Optimization</i>	121
5.2.5.5	<i>Model evaluation and Local Sensitivity Analysis</i>	122
5.2.6	<i>Pharmacodynamic evaluation</i>	123
5.2.6.1	<i>Drugs and treatment</i>	123
5.2.6.2	<i>Morris Water Maze Test</i>	123
5.2.6.3	<i>Biochemical parameter estimation and evaluation of hepatotoxicity</i>	124

5.2.6.4	<i>Statistical analysis</i>	124
5.3	Results and Discussion	125
5.3.1	<i>Solid-state Characterization</i>	125
5.3.1.1	<i>Powder X-Ray Diffraction Study</i>	125
5.3.1.2	<i>Differential Scanning Calorimetry Study</i>	125
5.3.1.3	<i>Transmission Electron Microscopy</i>	126
5.3.2	<i>High performance Liquid Chromatography (HPLC)</i>	127
5.3.3	<i>Biopharmaceutical performance evaluation</i>	128
5.3.3.1	<i>Saturation solubility study</i>	128
5.3.3.2	<i>In vitro dissolution testing</i>	129
5.3.3.3	<i>Plasma and brain pharmacokinetics in male rats</i>	130
5.3.4	<i>Rat PBPK model</i>	131
5.3.4.1	<i>Plasma and brain concentration for Rilutor™</i>	131
5.3.4.2	<i>Simulated vs observed plasma and brain concentration</i>	132
5.3.5	<i>Human PBPK Model</i>	132
5.3.5.1	<i>Concentration-time curve for Tablet</i>	132
5.3.6	<i>Local sensitivity analysis for rat and humans</i>	133
5.3.7	<i>Pharmacodynamic evaluation</i>	137
5.3.7.1	<i>Morris water maze test</i>	137
5.3.7.2	<i>Hepatotoxicity Evaluation</i>	138
5.4	Conclusions	139
Chapter 6		
6	Summary and conclusion	141
Chapter 7		
	References	147
	List of Publications	169